Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral antiviral agents has significantly improved the prognosis of patients with CHB infection and reduced the risk of HCC. However, hepatitis B virus still remains a major factor in the development of HCC, raising many concerns. Therefore, numerous studies have been conducted to assess the risk of HCC in patients with CHB infection and many models have been proposed to predict the risk of developing HCC. However, as each study has different models for predicting HCC development that can be applied depending on the use of antiviral agents or the type of antiviral agents, it is necessary to properly understand characteristics of each model when using it for the evaluation of HCC in patients with CHB infection. In addition, because different variables such as host factor, viral activity, and cirrhosis are used to evaluate the risk of HCC development, it is necessary to assess the risk by carefully verifying which variables are used. Recently, studies have also evaluated the risk of HCC using risk prediction models through transient elastography and artificial intelligence (AI) system. These HCC risk predication models are also noteworthy. In this review, we aimed to compare HCC risk prediction models in patients with CHB infection reported to date to confirm variables used and specificity between each model to determine an appropriate HCC risk prediction method.
Citations
Citations to this article as recorded by
Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular Carcinoma Ming-Ying Lu, Jacky Chung-Hao Wu, Henry Horng-Shing Lu, Mohammed Eslam, Ming-Lung Yu Gut and Liver.2026; 20(1): 5. CrossRef
Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W. Ray Kim, Leland J. Yee, Craig Brooks-Rooney, Tristan Curteis, Laura J. Clark, Zarena Jafry, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Wook Kim, Neung Hwa Par Clinical Gastroenterology and Hepatology.2025; 23(2): 310. CrossRef
Development and validation of an interpretable machine learning model for predicting the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study Linghong Wu, Zengjing Liu, Hongyuan Huang, Dongmei Pan, Cuiping Fu, Yao Lu, Min Zhou, Kaiyong Huang, TianRen Huang, Li Yang BMC Gastroenterology.2025;[Epub] CrossRef
Is AI‐Based Hepatocellular Carcinoma Prediction Ready for Prime Time? Xinrui Jin, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip Liver International.2025;[Epub] CrossRef
A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B Jiwon Yang, Mark D. Muthiah, Won-Mook Choi Current Hepatology Reports.2025;[Epub] CrossRef
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo Journal of Hepatology.2025; 83(2): 502. CrossRef
Rationalising Hepatocellular Carcinoma Screening in Chronic Hepatitis B: Evaluation of Predictive Scores in an Australian Cohort Thisuri Jayawardena, Zein Salim, Luis Calzadilla Bertot, Joanne Bunney, Nicolas Demasi, Joanne Vallve, Leon Adams, Gary Jeffrey, David Speers, Gerry MacQuillan, Tim Mitchell Liver International.2025;[Epub] CrossRef
Prediction Model for Familial Aggregated HBV‐Associated Hepatocellular Carcinoma Based on Serum Biomarkers Linmei Zhong, Guole Nie, Qiaoping Wu, Honglong Zhang, Haiping Wang, Jun Yan Cancer Reports.2025;[Epub] CrossRef
Applications of artificial intelligence in liver cancer: A scoping review Andrea Chierici, Fabien Lareyre, Antonio Iannelli, Benjamin Salucki, Sébastien Goffart, Lisa Guzzi, Elise Poggi, Hervé Delingette, Juliette Raffort Artificial Intelligence in Medicine.2025; 169: 103244. CrossRef
Combined Analysis of Protein Induced by Prothrombin Induced by Vitamin K Absence (PIVKA) and Alpha-L-Fucosidase (AFU) with Alpha-Fetoprotein (AFP) May Improve the Diagnostic Efficacy for Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Haisong Hou, Ruiqiang Weng, Liu Liang, Wendao Han International Journal of General Medicine.2025; Volume 18: 6031. CrossRef
LEAST as a novel prediction model of hepatocellular carcinoma development in patients with chronic hepatitis B: a multi-center study Jingjing Song, Jie Li, Zhigang Ren, Wen Xie, Jinhua Shao, Xiaoxiao Zhang, Yang Zhou, Fajuan Rui, Xiaoqing Wu, Qiuling Wang, Zuxiong Huang, Chao Sun, Yuemin Nan BMC Medicine.2025;[Epub] CrossRef
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B Ho Soo Chun, George V. Papatheodoridis, Minjong Lee, Hye Ah Lee, Yeong Hwa Kim, Seo Hyun Kim, Yun-Seo Oh, Su Jin Park, Jihye Kim, Han Ah Lee, Hwi Young Kim, Tae Hun Kim, Eileen L. Yoon, Dae Won Jun, Sang Hoon Ahn, Vana Sypsa, Cihan Yurdaydin, Pietro Lampe Journal of Hepatology.2024; 80(1): 20. CrossRef
Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study Yixin Hou, Jianguo Yan, Ke Shi, Xiaoli Liu, Fangyuan Gao, Tong Wu, Peipei Meng, Min Zhang, Yuyong Jiang, Xianbo Wang OncoTargets and Therapy.2024; Volume 17: 215. CrossRef
Optimizing care of HBV infection and HBV-related HCC Shi Yan Lee, Benjamin Kai Yi Nah, Jazleen Leo, Jia Hong Koh, Daniel Q. Huang Clinical Liver Disease.2024;[Epub] CrossRef
Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection Junjie Chen, Tienan Feng, Qi Xu, Xiaoqi Yu, Yue Han, Demin Yu, Qiming Gong, Yuan Xue, Xinxin Zhang Journal of Medical Virology.2024;[Epub] CrossRef
Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity Mi Na Kim, Beom Kyung Kim, Heejin Cho, Myung Ji Goh, Yun Ho Roh, Su Jong Yu, Dong Hyun Sinn, Soo Young Park, Seung Up Kim, Tyng-Yuan Jang PLOS ONE.2024; 19(8): e0307712. CrossRef
Viral Load–Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B Gi-Ae Kim, Young-Suk Lim, Seungbong Han, Gwang Hyeon Choi, Won-Mook Choi, Jonggi Choi, Dong Hyun Sinn, Yong-Han Paik, Jeong-Hoon Lee, Yun Bin Lee, Ju-Yeon Cho, Nae-Yun Heo, Man-Fung Yuen, Vincent Wai-Sun Wong, Stephen L. Chan, Hwai-I Yang, Chien-Jen Chen Annals of Internal Medicine.2024; 177(10): 1308. CrossRef
AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease Sheza Malik, Rishi Das, Thanita Thongtan, Kathryn Thompson, Nader Dbouk Journal of Clinical Medicine.2024; 13(24): 7833. CrossRef
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim Hepatology Communications.2023; 7(2): e0011. CrossRef
Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals Ke Shi, Ping Li, Qun Zhang, Yi Zhang, Yufei Bi, Xuanwei Zeng, Xianbo Wang Frontiers in Oncology.2023;[Epub] CrossRef
A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study Hao-dan Mao, Shu-qin Zheng, Su-hua Yang, Ze-yu Huang, Yuan Xue, Min Zhou PeerJ.2023; 11: e15014. CrossRef
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap Shen-Yung Wang Clinical and Molecular Hepatology.2023; 29(2): 349. CrossRef
The clinical management of hepatocellular carcinoma in China: Progress and challenges Shan Shan, Jidong Jia Clinical and Molecular Hepatology.2023; 29(2): 339. CrossRef
CAGE‐B and SAGE‐B models better predict the hepatitis B virus‐related hepatocellular carcinoma after 5‐year entecavir treatment than PAGE‐B Hye Yeon Chon, Han Ah Lee, Soo Young Park, Yeon Seok Seo, Sang Gyune Kim, Chang Hun Lee, Tae Hee Lee, Sang Hoon Ahn, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip, Lilian Yan Liang, In Hee Kim, Grace Lai‐Hung Wong, Seung Up Kim Journal of Digestive Diseases.2023; 24(2): 113. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You Clinical and Molecular Hepatology.2023; 29(3): 747. CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Liver International.2023; 43(8): 1813. CrossRef
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, Pietro Lampertico, Maria Buti, Claude B. Sirlin, Mindie H. Nguyen, Rohit Loomba Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 797. CrossRef
Surveillance for hepatocellular carcinoma: It is time to move forward Bo Hyun Kim, Yuri Cho, Joong-Won Park Clinical and Molecular Hepatology.2022; 28(4): 810. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Clin Mol Hepatol 2022;28(2):207-218. Published online November 24, 2021
Background/Aims We compared the post-treatment overall survival (OS) and recurrence-free survival (RFS) between patients with Child-Turcotte-Pugh (CTP) class-A and single small (≤3 cm) hepatocellular carcinoma (HCC) treated by surgical resection (SR) and radiofrequency ablation (RFA).
Methods We retrospectively analyzed 391 HCC patients with CTP class-A who underwent SR (n=232) or RFA (n=159) as first-line therapy for single small (≤3 cm) HCC. Survival was compared according to the tumor size (≤2 cm/2–3 cm) and the presence of cirrhosis. Inverse probability of treatment weighting (IPW) method was used to estimate the average causal effect of treatment.
Result s: The median follow-up period was 64.8 months (interquartile range, 0.1–162.6). After IPW, the estimated OS was similar in the SR and RFA groups (P=0.215), and even in patients with HCC of ≤2 cm (P=0.816) and without cirrhosis (P=0.195). The estimated RFS was better in the SR group than in the RFA groups (P=0.005), also in patients without cirrhosis (P<0.001), but not in those with HCC of ≤2 cm (P=0.234). The weighted Cox proportional hazards model with IPW provided adjusted hazard ratios (95% confidence interval) for OS, and the RFS after RFA versus SR were 0.698 (0.396–1.232) (P=0.215) and 1.698 (1.777–2.448) (P=0.005), respectively.
Conclusions SR was similar for OS compared to RFA, but was better for RFS in patients with CTP class-A and single small (≤3 cm) HCC. The RFS was determined by the presence or absence of cirrhosis. Hence, SR rather than RFA should be considered in patients without cirrhosis to prolong the RFS, although there is no OS difference.
Citations
Citations to this article as recorded by
Comparison of surgical resection and radiofrequency ablation for the treatment of small hepatocellular carcinoma (≤ 3 cm): an updated meta-analysis Long-Ao Dai, Min Sun, Tian Li, Dong Wei, Ren-Chao Zou Systematic Reviews.2026;[Epub] CrossRef
Radiofrequency ablation versus surgical resection as first-line treatment for very early stage hepatocellular carcinoma: a systematic review with meta-analysis. Eduardo Freitas Viana, Diego Falcão Araújo, Thiago Francischetto Ribeiro, Vaner Paulo da Silva Fonseca Pinheiro, Rodrigo Leal Alves, André Luiz Aleluia da Silva, Helma Pinchemel Cotrim, André Castro Lyra Surgical Oncology.2026; : 102359. CrossRef
Imaging Classification of Exophytic HCC and Our Experience with Microwave Ablation of Type 2 Lesions Soumil Singhal, Pallav Bhatter, Girendra Shankar, Anubhav Khandelwal, Sanjay Saran Baijal Indian Journal of Radiology and Imaging.2025; 35(01): 017. CrossRef
Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models Zhanna Zhang, Gongqiang Wu Clinical and Molecular Hepatology.2025; 31(1): e8. CrossRef
Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis Ming Yang, Guangjun Li, Kunlin Chen, Youwei Wu, Ting Sun, Wentao Wang International Journal of Surgery.2025; 111(5): 3456. CrossRef
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study Edoardo G. Giannini, Andrea Pasta, Laura Bucci, Maria Corina Plaz Torres, Giulia Pieri, Ciro Celsa, Angelo Sangiovanni, Fabio Piscaglia, Claudia Campani, Gabriele Missale, Gianpaolo Vidili, Giorgia Ghittoni, Filippo Pelizzaro, Francesco Giuseppe Foschi, F Digestive and Liver Disease.2025; 57(8): 1673. CrossRef
Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis Wenlong Yang, Xiaoyan Li, Xufang Tan International Journal of Hyperthermia.2025;[Epub] CrossRef
Liver resection versus radiofrequency ablation for hepatocellular carcinoma: A systemic review and meta-analysis Zheng He, Guolang Song, Guangchao Yang, Xuan Fu, Meng Tian, Yanhui Zhu Frontiers in Oncology.2025;[Epub] CrossRef
Engineered macrophage membrane-mimicking nanodrugs activate cGAS/STING pathway to reverse tumor immune suppression after incomplete radiofrequency ablation Wei-Hua Zhang, Lei Chen, Lin Gao, Ye-Ming Wu, Zhi-Cheng Jin, Jian-Jian Chen, Yan-Li An, Gao-Jun Teng Journal of Nanobiotechnology.2025;[Epub] CrossRef
Radiofrequency Ablation versus Surgical Resection in Elderly Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Jeong-Ju Yoo, Sujin Koo, Gi Hong Choi, Min Woo Lee, Seungeun Ryoo, Jungeun Park, Dong Ah Park Current Oncology.2024; 31(1): 324. CrossRef
Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies Qiuxia Wei, Shiyu Xiong, Wanrong Luo, Ming Liang, Baoming Luo Clinical and Experimental Medicine.2024;[Epub] CrossRef
Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma Jun Il Kim, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park, Jeong-Ju Yoo Digestive Diseases and Sciences.2024; 69(3): 1055. CrossRef
The Role of Laparoscopic Surgery in the Management of Hepatocellular Carcinoma Justin A. Steggerda, Steven A. Wisel, Nicholas N. Nissen, Georgios Voidonikolas, Kambiz Kosari Current Hepatology Reports.2024; 23(3): 378. CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Nomogram for predicting post-therapy recurrence in BCLC A/B hepatocellular carcinoma with Child-Pugh B cirrhosis Wenying Qiao, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu Frontiers in Immunology.2024;[Epub] CrossRef
Meta analysis of radiofrequency ablation versus surgical resection in small and large nodule of hepatocellular carcinoma Rino A. Gani, Maria Teressa, Refael A. Budiman, Kemal F. Kalista, Cosmas Rinaldi A. Lesmana HPB.2024; 26(10): 1216. CrossRef
Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397. CrossRef
Microwave Ablation of Recurrent Hepatocellular Carcinoma after Curative Surgical Resection Hamzah Adwan, Lars Hammann, Thomas J. Vogl Journal of Clinical Medicine.2023; 12(7): 2560. CrossRef
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation Carlo Bosi, Margherita Rimini, andrea Casadei-Gardini, Giorgio Ercolani Expert Review of Anticancer Therapy.2023; 23(5): 503. CrossRef
Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study Selena Y. Lin, Dina Halegoua-DeMarzio, Peter Block, Yu-Lan Kao, Jesse Civan, Fwu-Shan Shieh, Wei Song, Hie-Won Hann, Ying-Hsiu Su Diagnostics.2023; 13(9): 1537. CrossRef
Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study Ke Su, Qiuni Shen, Jian Tong, Tao Gu, Ke Xu, Han Li, Hao Chi, Yanlin Liu, Xueting Li, Lianbin Wen, Yanqiong Song, Qulian Guo, Jiali Chen, Zhenying Wu, Yi Jiang, Kun He, Lu Guo, Yunwei Han Annals of Hepatology.2023; 28(4): 101109. CrossRef
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef
Establishment and application of a survival rate graph model based on biomarkers and imaging indexes after primary hepatocellular carcinoma resection Yue Xu, Xiaoqin Yao, Jinmei Li, Guoyuan Zhang, Guangcheng Luo, Qiang Wang Cancer Medicine.2023; 12(12): 13329. CrossRef
Comparative Study of Long-Term Outcomes of Laparoscopic Liver Resection versus Radiofrequency Ablation for Single Small Hepatocellular Carcinoma Located in Left Lateral Segments of the Liver MeeYoung Kang, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Jinju Kim, Chang Jin Yoon Medicina.2023; 59(6): 1063. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang BMC Cancer.2023;[Epub] CrossRef
Comparison of Open versus Laparoscopic Approaches in Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation Yeshong Park, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, MeeYoung Kang, Jinju Kim Medicina.2023; 59(7): 1243. CrossRef
Tumor size and survival in intrahepatic cholangiocarcinoma treated with surgical resection or ablation Elishama N. Kanu, Kristen E. Rhodin, Sabran J. Masoud, Austin M. Eckhoff, Alex J. Bartholomew, Thomas C. Howell, Jiayin Bao, Nicholas T. Befera, Charles Y. Kim, Dan G. Blazer, Sabino Zani, Daniel P. Nussbaum, Peter J. Allen, Michael E. Lidsky Journal of Surgical Oncology.2023; 128(8): 1329. CrossRef
Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation: A Retrospective Cohort Study with Propensity Score-Matched Analysis Yeshong Park, Ho-Seong Han, Yoo-Seok Yoon, Chang Jin Yoon, Hae Won Lee, Boram Lee, MeeYoung Kang, Jinju Kim, Jai Young Cho Cancers.2023; 15(19): 4745. CrossRef
Characteristics and Outcomes of Elderly Hepatocellular Carcinoma Patients following Surgical Resection: Systematic Review and Meta-Analysis Elizabeth M. Garcia, Sanjna N. Nerurkar, Eunice X. Tan, Shaun Y.S. Tan, Ern-Wei Peck, Sabrina X.Z. Quek, Readon Teh, Margaret Teng, Andrew Tran, Ee Jin Yeo, Michael Le, Connie Wong, Ramsey Cheung, Daniel Q. Huang Digestive Diseases.2023; 43(2): 206. CrossRef
Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open Bo Hyun Kim Clinical and Molecular Hepatology.2022; 28(2): 174. CrossRef
Liver resection, radiofrequency ablation, and radiofrequency ablation combined with transcatheter arterial chemoembolization for very-early- and early-stage hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis for comparison of Yunlong Zhang, Yunlong Qin, Peng Dong, Houfa Ning, Guangzhi Wang Frontiers in Oncology.2022;[Epub] CrossRef
Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience Mauro Giuffrè, Enrico Zuliani, Alessia Visintin, Paola Tarchi, Paola Martingano, Riccardo Pizzolato, Deborah Bonazza, Flora Masutti, Rita Moretti, Lory Saveria Crocè Diagnostics.2022; 12(10): 2517. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2021;27(3):363-401. Published online June 22, 2021
Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719 Qinqin Qiao, Shuhua Shan, Huiqin Guo, Ning An, Jiangying Shi, Zhuoyu Li Food Research International.2026; 225: 118084. CrossRef
The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim Gut and Liver.2026; 20(1): 107. CrossRef
Imaging Evaluation for Steatotic Liver Disease Shin Mei Chan, Vitor F Martins, Kathleen Marsh, Kang Wang, Jake T Weeks, Aiguo Han, Meng Yin, Kathryn J. Fowler, Claude B. Sirlin, Cheng William Hong Korean Journal of Radiology.2026; 27(2): 137. CrossRef
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim Clinical Gastroenterology and Hepatology.2025; 23(1): 114. CrossRef
Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Alimentary Pharmacology & Therapeutics.2025; 61(3): 491. CrossRef
Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang Journal of Physical Activity and Health.2025; 22(3): 323. CrossRef
The Role of microRNA-22 in Metabolism Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen International Journal of Molecular Sciences.2025; 26(2): 782. CrossRef
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang Gut and Liver.2025; 19(1): 116. CrossRef
Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang Frontiers in Nutrition.2025;[Epub] CrossRef
Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong Clinical Epidemiology.2025; Volume 17: 53. CrossRef
Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim American Journal of Gastroenterology.2025; 120(10): 2321. CrossRef
Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin Heliyon.2025; 11(7): e43073. CrossRef
Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study Huiyul Park, Terry Cheuk-Fung Yip, Eileen L. Yoon, Grace Lai-Hung Wong, Hye Sun Lee, Vincent Wai-Sun Wong, Jimmy Che-To Lai, Dae Won Jun JHEP Reports.2025; 7(6): 101388. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang BMC Gastroenterology.2025;[Epub] CrossRef
Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang Acta Psychologica.2025; 256: 105041. CrossRef
Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study Jisuk Yun, Young‐Sun Min American Journal of Industrial Medicine.2025; 68(7): 588. CrossRef
Valorization of grape pomace by microbial fermentation: Composition, biological activities and potential applications for the food industry Kavindya Samarakoon, H.P. Vasantha Rupasinghe Journal of Food Composition and Analysis.2025; 144: 107656. CrossRef
Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya Preventive Medicine: Research & Reviews.2025; 2(4): 183. CrossRef
Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease? Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros World Journal of Stem Cells.2025;[Epub] CrossRef
The ameliorative effect of C-Kit+ hepatic endothelial cells with Mertk deficiency on nonalcoholic steatohepatitis Seng-Wang Fu, Yu-Xuan Gao, Hui-Yi Li, Jun-Cheng Wu, Zheng-Hong Li, Ming-Yi Xu Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(7): 167964. CrossRef
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2025; 31(3): 771. CrossRef
Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis Amria Mamdouh Mousa, Rehab Fikry Taher, Nermin Mohamed El-Sammad, Esraa Aly Balabel, Elham Mohamed Youssef, Ahmed Hassan Afifi, Sahar Samir Abdel-Rahman, Nayera Anwar, Sherien Kamal Hassan BMC Complementary Medicine and Therapies.2025;[Epub] CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek Journal of the American Heart Association.2025;[Epub] CrossRef
Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee Frontiers in Medicine.2025;[Epub] CrossRef
Exercise training improves metabolic and circulatory function in COPD patients with NAFLD: evidence from clinical and molecular profiling Yi-cai Qian, Xiaoxiang Liu, Panpan Liu, ShuYing Jia, Yi Ding, Cuiling Zhu, Jing He Frontiers in Medicine.2025;[Epub] CrossRef
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(5): 758. CrossRef
Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan International Journal of Molecular Sciences.2025; 26(19): 9625. CrossRef
Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min Journal of Clinical Medicine.2025; 14(20): 7284. CrossRef
Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas World Journal of Gastroenterology.2025;[Epub] CrossRef
Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim The Journal of Infectious Diseases.2024; 229(1): 108. CrossRef
A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes Hao-ming He, Shu-wen Zheng, Yi-nong Chen, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Yi-hong Sun Angiology.2024; 75(3): 219. CrossRef
Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan Steroids.2024; 203: 109330. CrossRef
Association between plant-based diets and risk of metabolic dysfunction–associated steatotic liver disease in Korean adults: A prospective cohort study Bayarmaa Nasan Ulzii, Kyungjoon Lim, Sangah Shin Nutrition.2024; 128: 112579. CrossRef
Extrahepatic malignancies in metabolic dysfunction‐associated fatty liver disease: A nationwide cohort study Min Kyung Park, Moon Haeng Hur, Hye‐Sung Moon, Hyunjae Shin, Sung Won Chung, Sungho Won, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim Liver International.2024; 44(3): 799. CrossRef
Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini Metabolites.2024; 14(1): 52. CrossRef
Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease I-Ting Wu, Wan-Ju Yeh, Wen-Chih Huang, Hsin-Yi Yang The Journal of Nutritional Biochemistry.2024; 126: 109583. CrossRef
Quality Evaluation of Metabolic-Associated Fatty Liver Disease
Guidelines and Expert Consensus Meijing Chen, Ying Chen, Dun Liu, Ka Li, Rong Hu, Jingyi Chen, Xiaoying Jiang, Jinqing Lin Hormone and Metabolic Research.2024; 56(07): 509. CrossRef
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies Xin Ding, Xu He, Bulang Tang, Tian Lan Chinese Medicine.2024;[Epub] CrossRef
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim JAMA Internal Medicine.2024; 184(4): 375. CrossRef
Mobile App–Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial Oh Young Kwon, Mi Kyung Lee, Hye Won Lee, Hyerang Kim, Jae Seung Lee, Yeonsoo Jang Journal of Medical Internet Research.2024; 26: e49839. CrossRef
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin Heliyon.2024; 10(5): e27325. CrossRef
Assessment of Hepatic Steatosis Using Ultrasound-Based Techniques: Focus on Fat Quantification Woo Sun Rou Clinical Ultrasound.2024; 9(1): 1. CrossRef
Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon Gut and Liver.2024; 18(2): 294. CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease Yaxin Li, Yitian Guo, Shiyun Tan Clinics and Research in Hepatology and Gastroenterology.2024; 48(4): 102320. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Sleep factors were associated with a higher risk of MAFLD and significant fibrosis Yaxin Li, Shiyun Tan Sleep and Breathing.2024; 28(3): 1381. CrossRef
Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo Journal of Agricultural and Food Chemistry.2024; 72(13): 7187. CrossRef
Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score Aryoung Kim, Danbee Kang, Sung Chul Choi, Juhee Cho, Dong Hyun Sinn, Geum-Youn Gwak, Ashraf Elbahrawy PLOS ONE.2024; 19(3): e0301126. CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun Hepatology Research.2024; 54(11): 1027. CrossRef
Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin Diabetes & Metabolism Journal.2024; 48(3): 449. CrossRef
An Exploration of the Treatment of Non-Alcoholic Fatty Liver Disease Based on Dietary Factors Wanzhou Yang, Y.-T. Yu, P.P. Piccaluga, S. Xie BIO Web of Conferences.2024; 111: 03024. CrossRef
Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong Diagnostics.2024; 14(11): 1083. CrossRef
Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun Journal of Hepatology.2024; 81(5): 772. CrossRef
A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease Hung-Tsung Wu, Chin-Shiang Tsai, Ting-Hsing Chao, Horng-Yih Ou, Liang-Miin Tsai Antioxidants.2024; 13(6): 746. CrossRef
Evaluation of pancreatic iodine uptake and related influential factors in multiphase dual-energy CT Chen Pan, Tao Yu, Heng Zhao, Jiani He, Xiaomei Lu, Haiyan Tang, Yang Hong, Chao Shang, Qijun Wu, Aoran Yang, Chunli Li, Minghui Zhou, Yu Shi European Radiology.2024; 34(12): 7609. CrossRef
Comparative effects of lifelong moderate-intensity continuous training and high-intensity interval training on blood lipid levels and mental well-being in naturally ageing mice Ling Yang, Wentao Lin, Xu Yan, Zhishang Zhang Experimental Gerontology.2024; 194: 112519. CrossRef
The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial Eunbyul Cho, Sunwoo Kim, Soonkyu Kim, Ju Young Kim, Hwa Jung Kim, Yumi Go, Yu Jung Lee, Haesol Lee, Siye Gil, Sung Kwon Yoon, Keonho Chu Nutrients.2024; 16(14): 2254. CrossRef
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni Hepatology International.2024; 18(S2): 922. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef
Barriers to care linkage and educational impact on unnecessary MASLD referrals Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun Frontiers in Medicine.2024;[Epub] CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef
Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
A new Korean nomenclature for steatotic liver disease
Clinical and Molecular Hepatology.2024; 30(Suppl): S214. CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease Dana Ivancovsky Wajcman, Christopher J. Byrne, John F. Dillon, Paul N. Brennan, Marcela Villota-Rivas, Zobair M. Younossi, Alina M. Allen, Javier Crespo, Lynn H. Gerber, Jeffrey V. Lazarus Hepatology.2024;[Epub] CrossRef
Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park Diagnostics.2024; 14(20): 2305. CrossRef
Pathogenesis and management of metabolic dysfunction-associated
steatohepatitis-related hepatocellular carcinoma: a narrative
review Han Ah Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Evaluation of hepatoprotective and nephroprotective activities of Castanopsis costata extract in rats Maulana Alkandahri, Asman Sadino, Ermi Abriyani, Faizal Hermanto, Zulpakor Oktoba, Muhammad Sayoeti, Putu Sangging, Diah Wardani, Nahrul Hasan, Suci Sari, Nurul Safitri, Windi Ikhtianingsih, Safitri Safitri Biomedical Reports.2024;[Epub] CrossRef
Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target Yuan Yao, Yunfeng Shen Open Life Sciences.2023;[Epub] CrossRef
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(2): 358. CrossRef
Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(7): 1873. CrossRef
The association of non‐alcoholic fatty liver disease between parents and adolescent children Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak Alimentary Pharmacology & Therapeutics.2023; 57(2): 245. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Reply Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(9): 2435. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults Sun Young Shim, Sun Jae Jung, Seung Up Kim, Hyeon Chang Kim Clinical Hypertension.2023;[Epub] CrossRef
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease” Won Sohn, Yong-Han Paik Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 179. CrossRef
Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee European Journal of Gastroenterology & Hepatology.2023; 35(4): 431. CrossRef
Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease Kenneth W. Chow, Pragyat Futela, Aryan Saharan, Sammy Saab Journal of Clinical and Experimental Hepatology.2023; 13(5): 783. CrossRef
Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Min-Kyu Kang, Min-Cheol Kim Medicina.2023; 59(2): 375. CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review George Chen, Bubu Banini, Albert Do, Joseph K. Lim Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(Suppl): S220. CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee Biomedicine & Pharmacotherapy.2023; 161: 114445. CrossRef
Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong Scientific Reports.2023;[Epub] CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim Metabolites.2023; 13(3): 444. CrossRef
Nonalcoholic fatty liver disease and non-liver comorbidities Richie Manikat, Mindie H. Nguyen Clinical and Molecular Hepatology.2023; 29(Suppl): s86. CrossRef
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease Peter Konyn, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S43. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Comparison between obese and non-obese nonalcoholic fatty liver disease Wah-Kheong Chan Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease Georg Semmler, Christian Datz, Michael Trauner Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis Yi-wen Shi, Jian-Gao Fan Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management Anja Geerts, Sander Lefere Clinical and Molecular Hepatology.2023; 29(Suppl): S276. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun BMC Gastroenterology.2023;[Epub] CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review Young-Joo Jin Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease Ji-Won Park, Ki Tae Suk Clinical and Molecular Hepatology.2023; 29(2): 408. CrossRef
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed Philipp Kasper, Münevver Demir, Hans-Michael Steffen Clinical and Molecular Hepatology.2023; 29(2): 390. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park Hepatology International.2023; 17(3): 626. CrossRef
Genetic association study identifies genetic variants for non-alcoholic fatty liver without comorbidities in the Korean population Yeon Jun Kim, Yoon Shin Cho Genes & Genomics.2023; 45(7): 847. CrossRef
Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study Goh Eun Chung, Eun Ju Cho, Min Joo Kim, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Endocrinology.2023;[Epub] CrossRef
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease Han Ah Lee, Hwi Young Kim International Journal of Molecular Sciences.2023; 24(11): 9324. CrossRef
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim Alimentary Pharmacology & Therapeutics.2023; 58(3): 322. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang BMC Gastroenterology.2023;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee Ultrasonography.2023; 42(3): 421. CrossRef
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients Mona Mohamed Ibrahim Abdalla World Journal of Gastroenterology.2023; 29(27): 4271. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
The correlation between NAFLD and serum uric acid to serum creatinine ratio Jangwon Choi, Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Nam Hun Heo, Gulali Aktas PLOS ONE.2023; 18(7): e0288666. CrossRef
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B Cheol‐Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon Alimentary Pharmacology & Therapeutics.2023; 58(7): 704. CrossRef
Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease Ho Soo Chun Gut and Liver.2023; 17(4): 485. CrossRef
KASL clinical practice guidelines for management of autoimmune hepatitis 2022
Clinical and Molecular Hepatology.2023; 29(3): 542. CrossRef
Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon Gut and Liver.2023; 17(4): 663. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim Trials.2023;[Epub] CrossRef
Associations of Serum Uric Acid Level With Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Liver Fibrosis in Korean Men and Women: A Cross-Sectional Study Using Nationally Representative Data Jun Myong Lee, Hye Won Kim, So Young Heo, Kyung Yi Do, Jun Deok Lee, Seul Ki Han, Soon Koo Baik, Moon Young Kim, Sei-Jin Chang Journal of Korean Medical Science.2023;[Epub] CrossRef
Statins for treatment of fatty liver disease: Recent advances Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi World Chinese Journal of Digestology.2023; 31(16): 659. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients Magdi A. Ali, Eman El-Abd, Mohamed Morsi, Mohamed M. El Safwany, Mohamed Z. El-Sayed European Journal of Hybrid Imaging.2023;[Epub] CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han Infectious Diseases and Therapy.2023; 12(10): 2387. CrossRef
Association between waist circumference trajectories and incident non-alcoholic fatty liver disease Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon Obesity Research & Clinical Practice.2023; 17(5): 398. CrossRef
Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He Hepatology Communications.2023;[Epub] CrossRef
Approach to Fatty Liver Disease in Patients with Type 2 Diabetes Ji Cheol Bae The Journal of Korean Diabetes.2023; 24(3): 107. CrossRef
Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production Dong Yun Kim, Jun Yong Park, Heon Yung Gee Experimental & Molecular Medicine.2023; 55(11): 2332. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek Journal of Yeungnam Medical Science.2023; 40(Suppl): S47. CrossRef
The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults Jisuk Yun, Soon-Chan Kwon Toxics.2023; 11(12): 965. CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity T.S. Krolevets, M.I. Syrovenko, M.A. Livzan Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43. CrossRef
Association of Hepatic Fat Deposition and Severity of Acanthosis Nigricans in Children and Adolescents with Obesity Junhyung Lee, Hye-ji An, Young-Gyun Seo, Hong Ji Song, Hye-Mi Noh, Yu-Jin Paek, Kyung Hee Park Korean Journal of Family Practice.2023; 13(4): 240. CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon Diabetes Research and Clinical Practice.2022; 184: 109208. CrossRef
Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious Suprabhat Giri, Harish Darak, Sunil Kasturi Digestive Diseases and Sciences.2022; 67(10): 4962. CrossRef
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do Biomedicines.2022; 10(3): 550. CrossRef
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis Heejoon Jang, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Joon Yeul Nam, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon Hepatology.2022; 76(2): 492. CrossRef
The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight? Sae Hwan Lee The Korean Journal of Gastroenterology.2022; 79(3): 138. CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(4): 101344. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour International Journal of Molecular Sciences.2022; 23(8): 4305. CrossRef
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae Clinical and Molecular Hepatology.2022; 28(2): 196. CrossRef
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Youn Huh, Yoon Jeong Cho, Ga Eun Nam Journal of Obesity & Metabolic Syndrome.2022; 31(1): 17. CrossRef
Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang Journal of Gastroenterology and Hepatology.2022; 37(8): 1624. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease Jun-Hyeon Byeon, Min-Kyu Kang, Min-Cheol Kim Healthcare.2022; 10(5): 850. CrossRef
Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease Kwang Seob Lee, Yongin Cho, Hongkyung Kim, Hyunkyeong Hwang, Jin Won Cho, Yong-ho Lee, Sang-Guk Lee Biomedicines.2022; 10(6): 1216. CrossRef
Risk of liver fibrosis in patients with prediabetes and diabetes mellitus Jongsin Park, Heon-Ju Kwon, Won Sohn, Ju-Yeon Cho, Soo Jin Park, Yoosoo Chang, Seungho Ryu, Byung Ik Kim, Yong Kyun Cho, Chen-Hua Liu PLOS ONE.2022; 17(6): e0269070. CrossRef
Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(5): 101362. CrossRef
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak Hepatology.2022; 76(6): 1746. CrossRef
Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo Annals of Surgical Treatment and Research.2022; 102(6): 353. CrossRef
A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia Eujin Kim, Cho-Hyun Hwang, Juyoung Lee, Eungyeong Jang, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2022; 43(2): 184. CrossRef
Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang Scientific Reports.2022;[Epub] CrossRef
Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data Taeyun Kim, Hyunji Choi, Jaejun Lee, Jehun Kim International Journal of Environmental Research and Public Health.2022; 19(14): 8398. CrossRef
Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions Jung Il Lee Gut and Liver.2022; 16(4): 497. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis Ji-Hee Haam, Yang-Im Hur, Young-Sang Kim, Kyoung-Kon Kim, Jee-Hyun Kang, Hae-Jin Ko, Yoon Jeong Cho, Hye-In Choi, Kyu Rae Lee, Jung Ha Park, Soo Hyun Cho, Jong-Koo Kim, Taesic Lee, Myung-Jae Seo, Yeong Sook Yoon, Yoobin Seo, Ga Eun Nam, Sun Hyun Kim International Journal of Environmental Research and Public Health.2022; 19(16): 10444. CrossRef
Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis Liu Han, Shifeng Fu, Jianglei Li, Deliang Liu, Yuyong Tan Frontiers in Medicine.2022;[Epub] CrossRef
Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang Annals of Occupational and Environmental Medicine.2022;[Epub] CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee Journal of Korean Medical Science.2022;[Epub] CrossRef
Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Healthcare.2022; 10(11): 2268. CrossRef
Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung Biomedicine & Pharmacotherapy.2022; 156: 113952. CrossRef
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Sangsoo Han, Miyoung Choi, Bora Lee, Hye-Won Lee, Seong Hee Kang, Yuri Cho, Sang Bong Ahn, Do Seon Song, Dae Won Jun, Jieun Lee, Jeong-Ju Yoo Gut and Liver.2022; 16(6): 952. CrossRef
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2022; 28(4): 814. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease Sun Young Kim, Subin Mun, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Sang-Heon Cho, Jin-Woo Lee Medicine.2022; 101(37): e30527. CrossRef
A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim The Journal of Internal Korean Medicine.2022; 43(4): 680. CrossRef
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2022; 28(4): 933. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy Pengyu Yao, Yajuan Liu Molecules.2022; 28(1): 272. CrossRef
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley Current Oncology.2022; 30(1): 48. CrossRef
Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Korean Patients Undergoing Bariatric Surgery Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo Journal of Metabolic and Bariatric Surgery.2022; 11(2): 63. CrossRef
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung Diagnostics.2021; 11(12): 2233. CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila PLOS ONE.2021; 16(8): e0255822. CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li Frontiers in Endocrinology.2021;[Epub] CrossRef
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim Nutrients.2021; 13(12): 4453. CrossRef
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim Cancers.2021; 13(18): 4567. CrossRef
There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended “metabolic (dysfunction)-associated fatty liver disease (MAFLD)” as a more appropriate term to describe fatty liver diseases (FLD) associated with metabolic dysfunction. During the definition change from NAFLD to MAFLD, subjects with FLD and metabolic abnormalities, together with other etiologies of liver diseases such as alcohol, virus, or medication who have been excluded from the NAFLD criteria, were added to the MAFLD criteria, while subjects with FLD but without metabolic abnormality, who have been included in the NAFLD criteria, were excluded from the MAFLD criteria. This means that there is an emphasis on the metabolic dysfunction in MAFLD which may underestimate the prognostic value of hepatic steatosis itself, whereas the MAFLD criteria might better identify subjects who are at a higher risk of hepatic or cardiovascular outcomes. However, non-metabolic risk NAFLD subjects who are excluded from the MAFLD criteria are missed from the diagnosis, and their potential risk can be the cause of future diseases. Although huge controversies remain, this review focused on summarizing recent studies that compared the clinical and prognostic characteristics between subjects with NAFLD and MAFLD.
Citations
Citations to this article as recorded by
Risk Assessment for Carotid Atherosclerosis in Asymptomatic Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Hana Park, Ji Young Lee, Sungwon Park, Hyo Jeong Lee, Suh Eun Bae, Jaeil Kim, Hye-Sook Chang, Jaewon Choe, Hye Won Park, Ju Hyun Shim Gut and Liver.2026; 20(1): 125. CrossRef
Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study Yaxuan He, Yu Cao, Zekai Chen, Rong Xiang, Fang Wang Scientific Reports.2026;[Epub] CrossRef
Research Progress of the Relationship between Metabolic-Associated Fatty Liver Disease and Colorectal Neoplasia 杨 包 Advances in Clinical Medicine.2025; 15(02): 1996. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
The utility of an artificial intelligence model based on decision tree and evolution algorithm to evaluate steatotic liver disease in a primary care setting A.C. Goulart, A.P. Alencar, G. Tunes, L.L.T. Bianchi, M.H. Miname, C.M. Padilha, J.M.S. Pescuma, A.L.C.C. Rodrigues, B.B. Henares, M.S. de Almeida, T.A.O. Machado, D.H. Syllos, Y.P. Wang, M. Rienzo Brazilian Journal of Medical and Biological Research.2025;[Epub] CrossRef
Prevalence and risk factors of metabolic associated fatty liver disease in lean patients with bipolar disorder: a retrospective cross-sectional study Weihong Lei, Jiahuan Li, Yiyi Liu, Ying Wang, Qing Wu Frontiers in Endocrinology.2025;[Epub] CrossRef
Tracking Mutual Interactions of Mitochondria/Lysosomes/Lipid Droplets in DILI and NAFLD with a Viscosity and Peroxynitrite-Sensitive Single Fluorescent Probe Chunhua Fan, Xionghao Xu, Bo Zhao, Tao Jiang, Tianxin Liu, Chaewoon Cho, Juyoung Yoon, Zhengliang Lu Analytical Chemistry.2025; 97(40): 21935. CrossRef
Redefining fatty liver as metabolic dysfunction-associated steatotic liver disease: Implications of nomenclature changes for patients with diabetes Tulio L Correa, Nikki Duong World Journal of Hepatology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink Cornelius J. Fernandez, Mohammed Alkhalifah, Hafsa Afsar, Joseph M. Pappachan Pathogens.2024; 13(1): 68. CrossRef
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng BMC Public Health.2024;[Epub] CrossRef
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung Scientific Reports.2024;[Epub] CrossRef
Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999-2018 Jie Pan, Feilong Wu, Mingtao Chen, Jinsen He, Yingying Gu, Lei Pei, Xuye Lai, Zhenfeng Zhang, Lili Yang Diabetes & Metabolism.2024; 50(6): 101562. CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park Diagnostics.2024; 14(20): 2305. CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies Wanghao Liu, Xiaoying Sun BMC Nephrology.2024;[Epub] CrossRef
Leukocyte telomere length decreased the risk of mortality in patients with alcohol-associated liver disease Jiahong Yi, Hui Guo, Chang Jiang, Junyi Duan, Ju Xue, Yue Zhao, Wenzhuo He, Liangping Xia Frontiers in Endocrinology.2024;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(7): 1873. CrossRef
Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes Scandinavian Journal of Gastroenterology.2023; 58(5): 521. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease Goh Eun Chung, Su Jong Yu, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Donghee Kim, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho BMC Medicine.2023;[Epub] CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review George Chen, Bubu Banini, Albert Do, Joseph K. Lim Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(Suppl): S220. CrossRef
Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria Jie Pan, Yijie Ding, Yan Sun, Qiuyan Li, Tianyi Wei, Yingying Gu, Yujia Zhou, Nengzhi Pang, Lei Pei, Sixi Ma, Mengqi Gao, Ying Xiao, De Hu, Feilong Wu, Lili Yang Journal of Clinical Medicine.2023; 12(6): 2126. CrossRef
Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women Yayun Lu, Lingxia Ge, Hao Yang, Yufeng He, Yujun Wang Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 607. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
MAFLD: How is it different from NAFLD? Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George Clinical and Molecular Hepatology.2023; 29(Suppl): S17. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives Shang-Chin Huang, Chun-Jen Liu Clinical and Molecular Hepatology.2023; 29(2): 320. CrossRef
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park Hepatology International.2023; 17(3): 626. CrossRef
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark International Journal of Obesity.2023; 47(8): 677. CrossRef
Differential risk of 23 site‐specific incident cancers and cancer‐related mortality among patients with metabolic dysfunction‐associated fatty liver disease: a population‐based cohort study with 9.7 million Korean subjects Goh Eun Chung, Su Jong Yu, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho Cancer Communications.2023; 43(8): 863. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes Yoosun Cho, Yoosoo Chang, Seungho Ryu, Sarah H. Wild, Christopher D. Byrne Liver International.2023; 43(11): 2445. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
Metabolic dysfunction: The silenced connection with fatty liver disease Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez Annals of Hepatology.2023; 28(6): 101138. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn International Journal of Cancer.2023; 153(8): 1448. CrossRef
Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease—Oxidative Stress and Inflammation Relevance Madalina Andreea Robea, Ioana-Miruna Balmus, Irina Girleanu, Laura Huiban, Cristina Muzica, Alin Ciobica, Carol Stanciu, Carmen Diana Cimpoesu, Anca Trifan Medicina.2023; 59(9): 1614. CrossRef
From Nonalcoholic Steatohepatits to Steatotic Liver Disease: A Long Way Helma Cotrim Diagnostics.2023; 13(19): 3104. CrossRef
Impact of
Porphyromonas gingivalis
-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
Linbo Liu, Yan Geng, Chaoliang Xiong Annals of Medicine.2023;[Epub] CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
Correlation between serum uric acid and body fat distribution in patients with MAFLD Min Tao, Jing Liu, Xingyu Chen, Qing Wang, Miao He, Wenwen Chen, Cong Wang, Lili Zhang BMC Endocrine Disorders.2023;[Epub] CrossRef
Increased detection rates of advanced colorectal adenoma in women with metabolic dysfunction-associated fatty liver disease Yan Gong, Juan Kang, Xinyan Wang, Yansong Zheng, Ying Sui, Wenping Lu Heliyon.2023; 9(11): e22391. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study Mengchen Xing, Yanlan Ni, Ye Zhang, Xiaoqian Zhao, Xin Yu Frontiers in Nutrition.2023;[Epub] CrossRef
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD Zifeng Yang, Juan Yang, Jingjing Cai, Xiao-Jing Zhang, Peng Zhang, Zhi-Gang She, Hongliang Li Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim Cancers.2022; 14(20): 5002. CrossRef
Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults Jeong-Ju Yoo, Eun Ju Cho, Goh Eun Chung, Young Chang, Yuri Cho, Sang-Hyun Park, Su-Min Jeong, Bo-Yeon Kim, Dong Wook Shin, Yun Joon Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu Journal of Clinical Medicine.2022; 11(4): 935. CrossRef
Non-alcoholic/Metabolic-Associated Fatty Liver Disease and Helicobacter pylori Additively Increase the Risk of Arterial Stiffness Ji Min Choi, Hyo Eun Park, Yoo Min Han, Jooyoung Lee, Heesun Lee, Su Jin Chung, Seon Hee Lim, Jeong Yoon Yim, Goh Eun Chung Frontiers in Medicine.2022;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(4): 101344. CrossRef
Empirically-Derived Dietary Patterns in Relation to Non-Alcoholic Fatty Liver Diseases Among Adult Participants in Amol, Northern Iran: A Structural Equation Modeling Approach Azam Doustmohammadian, Elham Pishgar, Cain C. T. Clark, Elham Sobhrakhshankhah, Mehdi Nikkhah, Amir Hossein Faraji, Nima Motamed, Mohsen Reza Mansourian, Bahareh Amirkalali, Mansooreh Maadi, Maryam Sadat Kasaii, Hamidreza Ebrahimi, Farhad Zamani Frontiers in Nutrition.2022;[Epub] CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa World Journal of Clinical Pediatrics.2022; 11(3): 221. CrossRef
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee Digestive Diseases and Sciences.2022; 67(10): 4919. CrossRef
From NAFLD to MAFLD: Not just a change in the name Jing Zeng, Jian-Gao Fan Hepatobiliary & Pancreatic Diseases International.2022; 21(6): 511. CrossRef
I148M variant of PNPLA3-gene is not associated with metabolic syndrome in patients with NAFLD in the Indian ethnicity Govardhan Bale, Sasikala Mitnala, Nagaraja Rao Padaki, Mithun Sharma, Anand V. Kulkarni, Smita C. Pawar, Nageshwar Reddy D, Ravikanth Vishnubhotla Human Gene.2022; 33: 201073. CrossRef
Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions Francesca Lanzaro, Stefano Guarino, Elisabetta D'Addio, Alessandra Salvatori, Josè Alberto D'Anna, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa World Journal of Hepatology.2022; 14(6): 1087. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Won Kim, Sang Min Park Gut and Liver.2022; 16(4): 589. CrossRef
New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Life.2022; 12(8): 1189. CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim Hepatology Research.2022; 52(12): 975. CrossRef
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Biomedicines.2022; 10(10): 2375. CrossRef
Non-alcoholic fatty liver disease: a global concern Gerri Mortimore Practice Nursing.2022; 33(9): 358. CrossRef
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study Dina Attia, Shereen Abdel Alem, Wafaa El‐Akel, Wael Abdel‐Razek, Mohamed Eslam, Yasser Fouad, Imam Waked Alimentary Pharmacology & Therapeutics.2022; 56(11-12): 1581. CrossRef
Comparison of non-invasive imaging methods and laboratory findings on non-alcoholic fatty liver disease (NAFLD) in childhood Caner DOĞAN, Meryem KEÇELİ BAŞARAN, Okan GÜRKAN, Seda GÜLEÇ GEYLANİ Journal of Health Sciences and Medicine.2022; 5(6): 1541. CrossRef
Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem Sébastien Le Garf, Véronique Nègre, Rodolphe Anty, Philippe Gual Biomedicines.2021; 9(12): 1915. CrossRef
The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease Ji-Yeon Seo, Jung-Ho Bae, Min-Sun Kwak, Jong-In Yang, Su-Jin Chung, Jeong-Yoon Yim, Seon-Hee Lim, Goh-Eun Chung Biomedicines.2021; 9(10): 1401. CrossRef
Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease Hee Kyung Shin, Jeong Hwan Park, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee, Won Kim Scientific Reports.2021;[Epub] CrossRef
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease Ho Soo Chun, Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Cachexia, Sarcopenia and Muscle.2021; 12(5): 1168. CrossRef
Diabetes and metabolic dysfunction-associated fatty liver disease Timothy M.E. Davis Metabolism.2021; 123: 154868. CrossRef
Functions of two distinct Kupffer cells in the liver Chunye Zhang, Shuai Liu, Ming Yang Exploration of Medicine.2021; : 511. CrossRef
The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis Goh-Eun Chung, Young Chang, Yuri Cho, Eun-Ju Cho, Jeong-Ju Yoo, Sang-Hyun Park, Kyungdo Han, Dong-Wook Shin, Su-Jong Yu, Yoon-Jun Kim, Jung-Hwan Yoon Biomedicines.2021; 9(12): 1948. CrossRef
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um
Clin Mol Hepatol 2021;27(2):346-359. Published online January 25, 2021
Background/Aims Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients.
Methods Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV).
Result s: Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group.
Conclusions BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).
Citations
Citations to this article as recorded by
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial” Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Prodrug strategies in developing antiviral nucleoside analogs R. Rama Suresh, Tuniyazi Abuduani, Mahesh Kasthuri, Zhe Chen, Zahira Tber, Mohammed Loubidi, HongWang Zhang, Longhu Zhou, Shaoman Zhou, Chenwei Li, Amita Kumari, Sijia Tao, John M. Wiseman, Selwyn J. Hurwitz, Franck Amblard, Raymond F. Schinazi RSC Medicinal Chemistry.2026; 17(1): 105. CrossRef
Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim Scientific Reports.2025;[Epub] CrossRef
Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Wo Clinical and Molecular Hepatology.2025; 31(3): 810. CrossRef
Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim Scientific Reports.2025;[Epub] CrossRef
Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients: Insights From a Nationwide Cohort Study Hyun Bin Choi, Jae Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim Journal of Korean Medical Science.2025;[Epub] CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim Alimentary Pharmacology & Therapeutics.2023; 58(1): 99. CrossRef
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient Jong Chul Kim, Hye Young Lee, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Juhee Won, Soree Park, Na Yeon Kim, Jae Jin Shin, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo, Kyun-Hwan Kim Biomedicines.2022; 10(2): 282. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir Juhee Won, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Jong Chul Kim, Soree Park, Nayeon Kim, Byengjune Jae, Kyun-Hwan Kim Biomedicines.2022; 10(7): 1637. CrossRef
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B Jeong Eun Song, Jun Yong Park Expert Opinion on Pharmacotherapy.2021; 22(18): 2427. CrossRef
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim Clinical and Molecular Hepatology.2021; 27(3): 402. CrossRef
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu Hepatology International.2024; 18(S2): 897. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
First
Prev
